CoChat

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study: Saxagliptin in T2DM and renal impairment: 52-week study

Open access
Nowicki, M., Rychlik, I., Haller, H., Warren, M., Suchower, L., Gause-Nilsson, I., Schützer, K-M. · 2011 · International Journal of Clinical Practice
Cited by 136

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Therapeutic options are limited for diabetes patients with renal disease. This report presents 52-week results from a study assessing the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus (T2DM) and renal impairment. DESIGN: Double-blind study in patients stratified by baseline renal impairment (moderate, severe or end-stage renal disease [ESRD] on haemodialysis) randomised to saxagliptin 2.5 mg once daily or placebo added to other antidiabetic drugs in use at baseline, including insulin. PATIENTS: A total of 170 adults with glycated haemoglobin (HbA(1c) ) 7-11% and creatinine clearance < 50 ml/min or ESRD were randomised and treated. MEASUREMENTS: Absolute changes in HbA(1c) and fasting plasma glucose (FPG) from baseline to week 52 were evaluated using analysis of covariance (ANCOVA) with last observation carried forward. Repeated-measures analyses were also performed. RESULTS: Adjusted mean decrease in HbA(1c) was greater with saxagliptin than placebo (difference, -0.73%, p < 0.001 [ANCOVA]). Reductions in adjusted mean HbA(1c) were numerically greater with saxagliptin than placebo in patients with renal impairment rated as moderate (-0.94% vs. 0.19% respectively) or severe (-0.81% vs. -0.49%), but similar to placebo for those with ESRD (-1.13% vs. -0.99%). Reductions in adjusted mean FPG were numerically greater with saxagliptin in patients with moderate or severe renal impairment. Saxagliptin was generally well tolerated; similar proportions of patients in the saxagliptin and placebo groups reported hypoglycaemic events (28% and 29% respectively). CONCLUSIONS: Saxagliptin 2.5 mg once daily offers sustained efficacy and good tolerability for patients with T2DM and renal impairment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1742-1241.2011.02812.x

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 34

  1. US Renal Data System, 2010, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States
  2. Soldatos, 2008, Diabetic nephropathy: important pathophysiologic mechanisms, Diabetes Res Clin Pract, 82, S75, 10.1016/j.diabres.2008.09.042 · DOI
  3. Thomaseth, 2008, Importance of glycemic control on the course of glomerular filtration rate in type 2 diabetes with hypertension and microalbuminuria under tight blood pressure control, Nutr Metab Cardiovasc Dis, 18, 632, 10.1016/j.numecd.2007.05.006 · DOI
  4. Davis, 2010, Determinants of severe hypoglycemia complicating type 2 diabetes: the Fremantle diabetes study, J Clin Endocrinol Metab, 95, 2240, 10.1210/jc.2009-2828 · DOI · Paper page
  5. Krepinsky, 2000, Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease, Am J Kidney Dis, 35, 500, 10.1016/S0272-6386(00)70204-6 · DOI
  6. Odegard, 2007, Considerations for the pharmacological treatment of diabetes in older adults, Diabetes Spectr, 20, 239, 10.2337/diaspect.20.4.239 · DOI
  7. GLUCOPHAGE®, 2009, GLUCOPHAGE® XR (Metformin Hydrochloride, Extended-Release Metformin Hydrochloride)
  8. Tahrani, 2009, Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus, Adv Ther, 26, 249, 10.1007/s12325-009-0014-9 · DOI
  9. Kirby, 2010, Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition, Clin Sci, 118, 31, 10.1042/CS20090047 · DOI · Paper page
  10. Onglyza® (saxagliptin), 2011, Full Prescribing Information
  11. Neumiller, 2010, Saxagliptin: a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus, Am J Health Syst Pharm, 67, 1515, 10.2146/ajhp090555 · DOI
  12. Rosenstock, 2009, Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes, Curr Med Res Opin, 25, 2401, 10.1185/03007990903178735 · DOI · Paper page
  13. Jadzinsky, 2009, Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial, Diabetes Obes Metab, 11, 611, 10.1111/j.1463-1326.2009.01056.x · DOI · Paper page
  14. DeFronzo, 2009, Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes, Diabetes, 58
  15. Göke, 2010, Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial, Int J Clin Pract, 64, 1619, 10.1111/j.1742-1241.2010.02510.x · DOI · Paper page
  16. Scheen, 2010, Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus, Diabetes Metab Res Rev, 26, 540, 10.1002/dmrr.1114 · DOI · Paper page
  17. Hollander, 2009, Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone, J Clin Endocrinol Metab, 94, 4810, 10.1210/jc.2009-0550 · DOI · Paper page
  18. Chacra, 2009, Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial, Int J Clin Pract, 63, 1395, 10.1111/j.1742-1241.2009.02143.x · DOI · Paper page
  19. Nowicki, 2011, Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment, Diabetes Obes Metab, 13, 523, 10.1111/j.1463-1326.2011.01382.x · DOI · Paper page
  20. Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580 · DOI · Paper page
  21. Levey, 2006, Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate, Ann Intern Med, 145, 247, 10.7326/0003-4819-145-4-200608150-00004 · DOI · Paper page
  22. U. K. Prospective Diabetes Study Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 · DOI · Paper page
  23. Pfützner, 2011, Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks, Diabetes Obes Metab, 13, 567, 10.1111/j.1463-1326.2011.01385.x · DOI · Paper page
  24. Göke, 2011, Saxagliptin vs glipizide as add-on therapy to metformin for type 2 diabetes mellitus (T2DM): long-term safety and efficacy [abstract], Diabetes, 60, A305
  25. Sharif, 2010, Diagnostic application of the A(1c) assay in renal disease, J Am Soc Nephrol, 21, 383, 10.1681/ASN.2010010031 · DOI
  26. Mirani, 2010, Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis, Diabetes Technol Ther, 12, 749, 10.1089/dia.2010.0052 · DOI
  27. McGill, 2010, Liraglutide: effects beyond glycaemic control in diabetes treatment, Int J Clin Pract Suppl, 64, 28, 10.1111/j.1742-1241.2010.02495.x · DOI
  28. Giorgino, 2011, Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies, J Endocrinol Invest, 34, 69, 10.1007/BF03346698 · DOI
  29. Jung, 2010, Analysis of hemodialysis-associated hypoglycemia in patients with type 2 diabetes using a continuous glucose monitoring system, Diabetes Technol Ther, 12, 801, 10.1089/dia.2010.0067 · DOI
  30. European Medicines Agency, 2004, Note for Guidance on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Renal Function
  31. U.S. Department of Health and Human Services Food and Drug Administration, 1998, Guidance for Industry. Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Impact on Dosing and Labeling
  32. Tatsuo, 2011, A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study, J Clin Rheumatol, 17, S27, 10.1097/RHU.0b013e31821d36f2 · DOI
  33. Gschwend, 2011, Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment, Invest Radiol, 49, 556, 10.1097/RLI.0b013e31821a218a · doi:10.1097/rli.0b013e31821a218a
  34. Boulton, 2011, Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin, Clin Pharmacokinet, 50, 253, 10.2165/11584350-000000000-00000 · DOI

Cited by

See all 136

Metadata

Authors
Nowicki, M., Rychlik, I., Haller, H., Warren, M., Suchower, L., Gause-Nilsson, I., & Schützer, K.-M.
Venue
International Journal of Clinical Practice
Published
2011-10-07
Volume
65
Issue
12
Pages
1230-1239
ISSN
1368-5031 (ISSN-L)
OpenAlex
W1596584892
Cited by
136
References
4
FWCI
14.12
Type
journal article
Language
en
Open access
bronze
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1425 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study: Saxagliptin in T2DM and renal impairment: 52-week study. https://app.cochat.ai/papers/10.1111/j.1742-1241.2011.02812.x
The paper
Nowicki, M., Rychlik, I., Haller, H., Warren, M., Suchower, L., Gause-Nilsson, I., & Schützer, K.-M. (2011). Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study: Saxagliptin in T2DM and renal impairment: 52-week study. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2011.02812.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.